Reviews and feature articleAllergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
Section snippets
Review/Consultation group
Agache I (Faculty of Medicine, Transylvania University, Brasov, Romania)
Ameille J (AP-HP, Unité de pathologie professionnelle, Hôpital Raymond Poincaré, Garches, France)
Bachert C (Upper Airway Research Laboratory, University Hospital Ghent, Belgium)
Baker A (Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada)
Bateman E (Department of Medicine, University of Cape Town, South Africa)
Ben Kheder A (Hopital A. Mami,
Objective
Our objective was to develop explicit, unambiguous, and transparent clinical and practical recommendations systematically for the treatment of AR on the basis of current best evidence following the GRADE approach. This article summarizes the ARIA recommendations, and the complete rationale and explanation of all recommendations are provided in the unabridged text of the ARIA guidelines in this article's Online Repository 1 at www.jacionline.org.
Methods
We previously described the methods of the ARIA 2010 Revision,9 and the detailed methods are also provided in the unabridged text of the guidelines in Online Repository 1. We followed the principles for developing transparent, evidence-based guidelines suggested by the World Health Organization.9, 10, 11
We used the previous version of the ARIA guidelines as a starting point for the identification of clinical questions.1 We followed the systematic approach suggested by the GRADE working group
Results
In this article, we present 10 recommendations about the primary, secondary, and tertiary prevention of allergy, AR, and asthma; 31 recommendations about the management of AR; and 7 recommendations about the management of AR and asthma in the same patient. In-depth explanations, search strategies, evidence syntheses, and rationales are presented in Online Repository 1 and this article's Online Repository 2 at www.jacionline.org.
Statements about the underlying values and preferences as well as
Discussion
The updated recommendations of the ARIA guidelines were developed by an international panel following the systematic and transparent GRADE approach.16, 17 The target audience of these guidelines is all physicians treating patients with AR, other health care professionals, health care policy makers,1, 13, 18 and patients.19 Our review of the literature identified many areas where there are few studies or only studies with a high risk of bias are available. We also identified many areas that
References (21)
- et al.
Allergic rhinitis and its impact on asthma
J Allergy Clin Immunol
(2001) - et al.
International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis
Prim Care Respir J
(2006) - et al.
The diagnosis and management of rhinitis: an updated practice parameter
J Allergy Clin Immunol
(2008) - et al.
Clinical experts or methodologists to write clinical guidelines?
Lancet
(2009) - et al.
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Allergy
(2008) - et al.
Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three
Allergy
(2009) - et al.
Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial
Allergy
(2003) - et al.
BSACI guidelines for the management of allergic and non-allergic rhinitis
Clin Exp Allergy
(2008) - et al.
An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations
Am J Respir Crit Care Med
(2006) - et al.
Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update
Allergy
(2008)
Cited by (0)
J.B., S.B., G.W.C., R.GvW., H.J.S., and T.Z. are members of the Global Allergy and Asthma European Network supported by European Commission Framework Programme grant FOOD-CT-2004-506378.
Disclosure of potential conflict of interest: J. L. B. is a member of the GRADE working group; he is an editor of a clinical journal where various drugs are advertised, including those that are the subject of these guidelines; he received honoraria for speaking at conferences and travel reimbursement from GlaxoSmithKline and i3 Research and for expert panel participation from Boehringer Ingelheim. J. B. received fees and honoraria for lectures, expert panel participation and consultations from Allmiral, ALK, AstraZeneca, Chiesi Farmaceutici, Faes Pharma, GlaxoSmithKline, Meda, Merck Sharp and Dohme, Mundifarma, Novartis, Nycomed-Altana, Roche, Sanofi-Aventis, Stallergènes, Schering- Plough, Teva, UCB and Uriach. C. E. B-C. received fees for consultancy, speaker bureau participation, lectures and research grants from Abello, ALK, FAES (Spain), GlaxoSmithKline, Grünenthal (Venezuela), Lofarma (Italy), Merk Serono, MSD, Novartis, Phoenix (Argentina), Sanofi-Aventis, Schering-Plough, and Uriach (Spain). S. B. received consultancy fees and honoraria for editorial activity or participation in sponsored symposia from: ALK, Almirall, AstraZeneca, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Nycomed, Phadia, Schering-Plough, Sigma Tau and Stallergens. G. W. C. received fees and honoraria for lectures, expert panel participation and consultations and research support from A. Menarini, Alcon, Alk-Abellò, Almirall, Anallergo, AstraZeneca, Biofutura Pharma, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Lofarma, Merck Sharp & Dome, Novartis, Nycomed, Pfizer, Phadia, Schering Plough, SigmaTau, Stallergenes, UCB Pharma, Uriach and Valeas. T. C. declares no potential conflict of interest. R.GvW. received fees for lectures, expert panel participation and consultancy from Allergopharma, Allmiral, Alcon, Crucell, Hal, Merck Sharp & Dome, Novartis, Stallargènes and UCB. K. O. received fees and honoraria for lectures, expert panel participation and consultations from AstraZeneca, GlaxoSmithKline, Merck Banyu, Novartis, Schering Plough, Kyorin, Otsuka, and Taisho. H. J. S. is co-chair of the GRADE working group and he supports the implementation of the GRADE approach worldwide. From non-profit organizations he has accepted honoraria and consulting fees for activities in which his work with GRADE is relevant. In the past five years, H. J. S. received no personal payments for service from pharmaceutical for profit organizations. No financial support was received for the preparation of the evidence profiles or provided to the evidence synthesis team that HJS led as part of this work. T. Z. has received fees for consulting from Ansell, Bayer Schering, DST, Fujisawa, HAL, Henkel, Kryolan, Leti, Merck Sharp & Dohme, Novartis, Procter & Gamble, Sanofi-Aventis, Schering Plough, Stallergenes and UCB Pharma. None of the ARIA panel members have received any financial support for the work on these guidelines.